Pharma Sources Insight December 2021: From the Editor

Dear Readers,

As of today, COVID-19 has swept most countries and areas in the world with over 246 million cases of Coronavirus Disease and nearly 5 million deaths reported, according to WHO.

Statistics show that, as the result of the pursue to develop effective vaccines to protect people from the virus, there are 21 vaccines now in use, 82 vaccines in total are in Phase 2 and Phase 3 trials, and another 10 vaccines are being monitored in the wider population after being approved. If you are interested in vaccine R&D, you might find it useful to read “Where Are the  Oral COVID-19 Vaccines Stand Now” by Dr. Lin Zhang and Demand for High-End COVID-19 Vaccines to Drive Growth of Excipients Market by Shem Oirere.

Meanwhile, treatments are still “developed to finetune the right cocktail of medications to treat patients with COVID-19”, according to Deborah Seah, in the article “Progress of Research on Key COVID-19 Treatments”.

Here comes a question mark, “Has COVID been Injecting Cash into Pharma”?

Inspired by the success of mRNA vaccines, “the Application of mRNA Technology has Become a Hot Field in China”. In China, A series of incentive policies such as centralized procurement, MAH system have encouraged the pharmaceutical companies to embark on a race of new drug development and innovation. In December Issue, on the one hand, we are going to look at “Sustainable Development Capacity Building of Pharmaceutical Enterprises from the Perspective of R&D Expenditure” (Page N). On the other hand, what catches our attention is how “Innovative Drugs of Chinese Pharmaceutical Companies have Obtained Overseas Authorization and Developed Rapidly”.

To drug discovery nowadays, speed is everything. Technology development, for instance, Quantum Computing, provides an enormous potential of not falling behind at the starting line for the pharmaceutical industry. Quantum seems to have permeated to every corner in the advance of science, and pharma is with no difference. In Industry Insight, Dr. Sarah Harding will introduce “How is Quantum going to impact pharma?” and “Why is it better than normal computing?”.

The year 2021 will come to an end, but our exploration in the pharmaceutical industry will not. Gathering elite writers to produce high-quality pharma content, PharmaSources will continue its effort to update developments and trends in the Chinese Pharmaceutical Industry and provide a link for the world pharmaceutical industry to connect with sources of Chinese pharmaceutical products.

Last but not least, our sincerest thanks to the strong support of PharmaSources contributors and the dearest readers of PSI. Thank you for hearing us!

Editor in Chief,

PharmaSources